Aktuellt
SENASTE
During 2023 STENOCARE delivered record in gross sales amounting to DKK 6.9m, corresponding to a growth of 18%, in combination with a decreasing cost base. For 2024 we estimate net sales of DKK 16.5m driven by, among other things, new products in Australia and Denmark as well as introduction of the first product in Germany, resulting in a positive EBITDA-result at the end of the year. With estimated net sales of DKK 66.6m by 2026, and with an applied P/S multiple of 5x, a potential present value per share of DKK 8.8 (9.4) is derived in a Base scenario.
LÄS MER
